With All Chips On Phase II Antibody Conjugate, CuraGen Eyes Strategic Options
Biotech’s cash coffers are well stocked, but out-license of GPNMB-targeting cancer drug – or outright sale of the company – could be next.
Biotech’s cash coffers are well stocked, but out-license of GPNMB-targeting cancer drug – or outright sale of the company – could be next.